undamentalytics Newsletter
Sign in

Aytu Biopharma, Inc balance sheet

At the end of fiscal 2026, Aytu Biopharma, Inc had total assets of $105m and shareholders' equity of $35.3m. It held $26.3m in cash against $17.0m of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 20252026Jun 2026
Cash and equivalents378171148501923203126
Receivables—001126282229243123
Inventory—011111016111212117
Total current assets38103915751056073627962
Goodwill—000—0286600———
Total assets121824152135153266138136118124105
Accounts payable1—22221219—13101111
Deferred revenue (current)000—00000————
Total current liabilities6110435291096469626355
Short-term debt—————01—40222
Long-term debt—0——0000151511119
Total debt00100015251917152217
Total liabilities731411828581289397———
Shareholders' equity516104137951384439281935
Shares outstanding——9m—72m————6m12m—11m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AQST vs AYTUAYTU vs DERMAYTU vs RMTI

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Aytu Biopharma, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aytu Biopharma, Inc.